Treatment Landscape for Malignant Pleural Mesothelioma: Current Options and Future Directions

This NEJM review covers the multimodal management of malignant pleural mesothelioma, including surgery, chemotherapy, immunotherapy, and emerging molecular targets. For pathology and molecular labs, accurate histological subtyping (epithelioid, sarcomatoid, biphasic) and BAP1 loss/CDKN2A deletion testing by IHC and FISH are critical for prognosis and increasingly for immunotherapy selection.